EU Portal and Database Update

Similar documents
Clinical Trial Safety Reporting requirements

CT Regulation: EMA role

EudraVigilance: Preparing for Change

EudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables

EU Clinical Trial Regulation A view from the Industry

Signal Management in the EU and future extended access to EudraVigilance for industry

The new EudraVigilance System Public Communications Plan for EMA and National Competent Authorities in the EEA

EudraVigilance auditable requirement project

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Medical Literature Monitoring

Conditional marketing authorisation

EudraVigilance auditable requirement project: ADRreports.eu portal update

Overview of the Agency s role, activities and priorities for An agency of the European Union

EudraVigilance Registration Updates

Scientific and Regulatory Evaluation Procedure Support [S-REPS] Pilot Update / System Preview

Guidance on preparing for Brexit in the centralised procedure

Pilot of MAH signal detection in EudraVigilance

Publication of Risk Management Plan (RMP) summaries:

Pharmacovigilance: Information systems and services

SPOR data management services - high level changes

Update on EMA Brexit preparedness

Federal agency for medicines and health products

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

New pharmacovigilance systems and services

EMA perspective on Quality Metrics

EMA role in GMP Manufacturing and Quality Compliance

EMA Working Groups on Committees' Operational Preparedness

Date : Date of start of procedure: Authorisation/ positive opinion :

Pharmacovigilance. An agency of the European Union

PRIority MEdicines (PRIME)

Pharmacovigilance: Information systems and Services

Feedback on EudraVigilance & new functionalities

Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016)

Marketing Authorisation Routes in the EU

Recent update of the guidance for Parallel EMA/FDA scientific advice

Monthly statistics report: December 2017

Monthly statistics report: November 2016

EMA on social media. Monika Benstetter, Head of Media and Public Relations Communications Department. An agency of the European Union

Publication of Risk Management Plan (RMP) summaries:

Strengthening the prospective discussions on post-licensing evidence generation

Substance & Product Management Services (P&SMS) update

Engagement with stakeholders

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

SME info day: The new clinical trial regulation

Update on preparation for Signal Management

Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Five years as EMA Liaison at US FDA

EU regulatory tools for expedited antibacterial development programmes

Pharmacovigilance and product data

GUIDANCE FOR THE PREPARATION OF GOOD CLINICAL PRACTICE INSPECTION REPORTS

Report from EMA industry survey on Brexit preparedness

Priority Medicines (PRIME) scheme

A Regulatory Approach to Validation of the CDM

PRIME. 7 th STAMP meeting Brussels, 27 th June Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division

Date: Date of start of procedure: Authorisation/ positive opinion: Date: Date:

The role of patients at the EMA

Considerations on regulatory aspects

EMA action plan related to the European Commission s recommendations on product information 1

Issues identified by stakeholders: follow-up from EMA s ATMP workshop

Highlights of the proposed Clinical Trials Regulation in Europe

ENCePP Code of Conduct Revision 4

The future clinical trial authorisation process: the new evaluation process

Work plan for the CVMP Pharmacovigilance Working Party (PhVWP-V) 2018

STANDARD OPERATING PROCEDURE

CTFG 10 September 2010

Comments from: Name of organisation or individual. Merck Sharp & Dohme (MSD)

Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017

Brexit Guidance for Stakeholders Human and veterinary medicines

Scientific advice and its impact on marketing authorisation application reviews

Advanced Therapies in Europe

We appreciate the opportunity to submit these comments for your consideration.

Draft document circulated to Committees drafting group members 20 October Committees consultation November Adoption January 2015

Redistribution of the UK centrally authorised product portfolio

Life cycle of a clinical trial. IMB Clinical Trial Seminar June 19 th Dr. Agnieszka Przybyszewska, MD, MSc, PhD, PGDipPharmMed.

Ethical considerations for clinical trials on medicinal products conducted with the paediatric population

EMA/CAT support to ATMP developers

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

International Supply Chain: How are we handling globalisation? GCP oversight

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

Pharmacovigilance System Master file

ENVIRONMENTAL RISK ASSESSMENTS: EU CLINICAL TRIALS WITH GMO-BASED ATMPS ANN GORMAN, AMGEN LTD, UK 16 DECEMBER 2016

II. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD

Standard operating procedure

EMA and international cooperation

New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change

Questions and answers on preparation, management and assessment of periodic safety update reports (PSURs)

Work plan for the GMP/GDP Inspectors Working Group for 2017

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

Danish Act on Clinical Trials of Medicinal Products 1

What are the real-world evidence tools and how can they support decision making?

EMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)

Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products)

European Medicines Agency decision

Work plan for the GMP/GDP Inspectors Working Group for 2018

Furthermore, the level of information and the subsequent assessment will vary on a case by case basis.

Submission of comments on 'Reflection paper on risk based quality management in clinical trials' (EMA INS/GCP/394194/2011)

Explanatory note on fees payable to the European Medicines Agency

Date : Date of start of procedure: Authorisation/ positive opinion :

Review of EU Clinical Trial Directive. 15 May 2012 Mike Beckers Sidley Austin LLP, Brussels

Transcription:

EU Portal and Database Update TOPRA 4 October 2017 Presented by Noémie Manent on 4 October 2017 Committees and Inspections Department An agency of the European Union

Table of content EMA Portal and Database status update The detailed functionalities for Sponsors Conclusions 1 EU Portal and Database Update

EU Portal and Database Update 2 EU Portal and Database Update

Collaborative working The EMA is working collaboratively EUROPEAN COMMISSION EUROPEAN MEDICINES AGENCY MEMBER STATES & ETHICS COMMITEES STAKEHOLDERS - Sponsors - CROs - Health Care Professionals - Patient Representatives 3 to develop systems to implement the regulation EU Portal and Database Update

Eu Portal and Database Update key milestones System Release 0.6 UAT dates: 6 Nov 27 Nov 2017 System Release 0.7 UAT Dates: end of Q1 2018 The audit of the EU portal and database : Q2 2018 The purpose of the audit is to confirm that the EU Portal and Database have achieved full functionality and the system meets the functional specifications which are defined in the document Functional Specifications of the EU Portal and EU Database to be audited (EMA/42176/2014 Rev.1, Corr.). System Release 0.8 UAT dates: beg of Q3 2018 EMA MB to endorse the results of the audit EU portal and database Launch: 2019 (actual date to be 6 months after the notice referred to in Article 82(3) of the CT regulation No. 536/2014 is published) 4 EU Portal and Database Update

Detailed Functionalities 5 EU Portal and Database Update

EU portal and database System interfaces MSs Sponsors CT Portal/EU DB WHO EMA Business Processes User Registration & Security (IAM) User Interfaces CT System Master Data Management (RMS/OMS) CT DB Public DB 6 Data Warehouse (DWH) EU Portal and Database Update Document Management (DMS) EV Human

Activities in the system Submit application (CTA dossier) / Address request for information Submission of CSR Submission of Union Control Reports Notification of willingness to be RMS (part I) / Decision on RMS Update of Clinical Trial information (re non substantial modifications) Submit notifications: Start of trial First visit first subject End of recruitment End of trial (in each MS, All MS, Global) Temporary halt & restart Serious Breach, Unexpected event, urgent safety measure Inspection from third country inspectorate Submission of clinical study result (summary and lay person summary) 7 EU Portal and Database Update Applicant of a MA Sponsors General public EMA Commission Member States Search and view CT information System Maintenance Submission of requests for information Notification of the final validation (initial, additional MS or Substantial Modification) Submission final AR conclusion Part 1 and to 2 Part I and Part II Final single decision notification Submission Inspection Information Communication disagreement to part 1 assessment Communication on implementation of corrective measures

User management 8 EU Portal and Database Update

EU portal and database User management hierarchy A structured top-down approach to maintain the integrity of the system EMA validates High-level administrators (Sponsors, Member States, EU Commission, MAHs) Approves Medium-level administrators (Sponsor Clinical trial and MS national organisation administrators) Approves Assign new role/ct access Amend role/ct access Revoke role/ct access Approve/reject user requests for a role (only applicable to sponsor users) Role allocated to perform activities in the system Regular users Regular users Regular users

Creation of clinical trial applications, responding to RFI, submit trial notification (e.g. trial start) and viewing the clinical trials 12 EU Portal and Database Update

The left inside panel now displays the member states concerned

Actions by the user Lock/unlock Left inside navigation Right inside navigation

Verification of the completion of the dossier before submission

Confirmation message once the user has clicked submit

The Public View 26 EU Portal and Database Update

Advanced search

Training 31 EU Portal and Database Update

CT Programme: Training principles and approach Online training Face - to - face Training colleagues On-going support Details Details Details Details Enable submission of dossier in 1 day Online material: - demo videos, - test environment, - user manuals, - guidance documents - in-system information Tailored training of Lead trainers Provided by training concessionaire 2-3 days for commercial sponsors 1 day for SME s & noncommercial sponsors Lead trainers use knowledge and online material to train colleagues Online material (refer to the Online training section) The EMA provides ongoing support through Webinars, Query management, etc. Targeted at: Targeted at: Targeted at: Targeted at: All stakeholders Large commercial sponsors SME s Primary focus of training Non-commercial sponsors 32 EU Portal and Database Update Member States Large commercial sponsors SME s Non-commercial sponsors All stakeholders

Off site and on-site UAT approach 33 EU Portal and Database Update

Key Objectives MS & sponsor orgs represented in UAT with on-site testing and off-line testing (37 testers/uat6) Interactive and E2E scenarios Sponsors - MSC Additional features tested Testing date: 6 Nov 27 Nov 2017 with collection of feedback on an on-going basis UAT 6 bugs to be with our developer before 22-Dec- 2017 34 EU Portal and Database Update

UAT 6 Timeline Key Dates and Information UAT 6 Webinar Details Communication w/c 18-Sep-2017 UAT 6 Off-site Execution 06-Nov-2017 to 27-Nov-2017 UAT 6 Provisional Webinar Dates w/c 16-Oct-2017 EMA Management Board Meeting 13-Dec-2017 to 14-Dec-2017 UAT 6 On-site Execution (and Support) 06-Nov-2017 to 10-Nov-2017 UAT 6 Completion Report Preparation w/c 11-Dec-2017 35 EU Portal and Database Update

Conclusions 36 EU Portal and Database Update

Conclusions: Harmonisation: One single submission for authorisation of a clinical trial to and for public registration (primary register of clinical trials); Member state collaboration: Facilitate cooperation among MSCs One single decision per Member State; IT maintenance: EMA to maintain and update the IT platforms; Public data and information about medicines, their development and authorisation To generate trust information is available To build confidence I understand what is happening To empower knowledge enables decision-making 37 EU Portal and Database Update

For more information: http://www.ema.europ a.eu/ema/index.jsp?cu rl=pages/regulation/ge neral/general_content_ 000629.jsp&mid=WC0 b01ac05808768df 38 EU Portal and Database Update

Any questions? Further information Noemie.manent@ema.europa.eu European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact Follow us on @EMA_News